ProBioGen  and Tizona Therapeutics have signed a commercial license and service agreement for cell line and process development. ProBioGen will develop Tizona’s immuno-oncology antibody up to GMP manufacturing, using its GlymaxX cell line to boost the antibody’s ADCC anti-tumor activity.   The program will follow ProBioGen’s development path, which, according to the company, allows selecting superior, stable producer clones with robust process features in reduced time, facilitating the earlier...